Iizuka, Yusuke https://orcid.org/0000-0003-1994-0222
Inoue, Minoru
Kokubo, Masaki https://orcid.org/0000-0002-6312-6757
Sakamoto, Takashi
Murofushi, Keiko Nemoto
Imagumbai, Toshiyuki
Shimizuguchi, Takuya https://orcid.org/0000-0001-9763-0743
Hiraoka, Masahiro
Mizowaki, Takashi https://orcid.org/0000-0002-8135-8746
Funding for this research was provided by:
Japan Agency for Medical Research and Development (15ck0106035, 17ck0106303, 20ck0106626)
Article History
Received: 4 December 2024
Accepted: 2 March 2025
First Online: 21 March 2025
Declarations
:
: Masaki Kokubo is in a speaker’s bureau for AstraZeneca K.K., Hitachi, Ltd, Varian Medical Systems, Inc., and Daiichi Sankyo, Ltd. Takashi Sakamoto is in a speaker’s bureau for SCETI K.K. Takashi Mizowaki has received honoraria from Varian Medical Systems, Inc., Elekta K.K., Hitachi, Ltd., and Brainlab AG; had a consulting or advisory role for Varian Medical Systems, Inc. Hitachi, Ltd.; and has received research funding from Hitachi, Ltd. and educational projects from Varian Medical Systems, Inc. and Brainlab AG. The other authors have no relevant financial or non-financial interests to disclose.
: This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the institutional review board of Kyoto University Graduate School and the Faculty of Medicine. (22nd Apr. 2021; approval number R-2944).
: Informed consent was obtained again from the patients who continued to visit the hospital for follow-up evaluations; for patients who could not be followed up due to death or other reasons, consent was obtained based on the opt-out procedures described on the hospital’s website.
: Informed consent for the publication of anonymized data was obtained from the patients who provided consent to participate. For patients who could not be followed up due to death or other reasons, consent for publication was obtained through opt-out procedures in accordance with the guidelines posted on the hospital’s website.